{
    "id": 25840,
    "fullName": "TP53 C238F",
    "impact": "missense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "TP53 C238F lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). C238F demonstrates decreased Tp53 transactivation activity in cell culture (PMID: 25634208), and therefore is predicted to confer a loss of function to the Tp53 protein.",
            "references": [
                {
                    "id": 2397,
                    "pubMedId": 22713868,
                    "title": "Mutant p53: one name, many proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22713868"
                },
                {
                    "id": 12248,
                    "pubMedId": 25634208,
                    "title": "Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25634208"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7157,
        "geneSymbol": "TP53",
        "terms": [
            "TP53",
            "BCC7",
            "BMFS5",
            "LFS1",
            "P53",
            "TRP53"
        ]
    },
    "variant": "C238F",
    "createDate": "12/27/2016",
    "updateDate": "09/20/2018",
    "referenceTranscriptCoordinates": {
        "id": 94013,
        "transcript": "NM_000546",
        "gDna": "chr17:g.7674250C>A",
        "cDna": "c.713G>T",
        "protein": "p.C238F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9806,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived fallopian tube cancer cells harboring TP53 C238F in culture (PMID: 27179933).",
            "molecularProfile": {
                "id": 26954,
                "profileName": "TP53 C238F"
            },
            "therapy": {
                "id": 3443,
                "therapyName": "APR-246 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1964,
                "name": "fallopian tube cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7621,
                    "pubMedId": 27179933,
                    "title": "Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27179933"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19435,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with melanoma harboring BRAF V600E developed progressive disease after 12 weeks of Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment, and progressed again after 106 weeks on anti-PD1 therapy including Opdivo (nivolumab) (90 weeks) followed by Keytruda (pembrolizumab), B2M V5Lfs*30, LRP1B W1344*, MAP2K2 F133L, NF2 Y66*, and TP53 C238F were identified in the post-progression biopsy in addition to BRAF V600E (PMID: 31082388).",
            "molecularProfile": {
                "id": 34105,
                "profileName": "B2M V5Lfs*30 BRAF V600E LRP1B W1344* MAP2K2 F133L NF2 Y66* TP53 C238F"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17019,
                    "pubMedId": 31082388,
                    "title": "Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31082388"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19436,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with melanoma harboring BRAF V600E developed progressive disease after 12 weeks of Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment, and progressed again after 106 weeks on anti-PD1 therapy including Opdivo (nivolumab) (90 weeks) followed by Keytruda (pembrolizumab), B2M V5Lfs*30, LRP1B W1344*, MAP2K2 F133L, NF2 Y66*, and TP53 C238F were identified in the post-progression biopsy in addition to BRAF V600E (PMID: 31082388).",
            "molecularProfile": {
                "id": 34105,
                "profileName": "B2M V5Lfs*30 BRAF V600E LRP1B W1344* MAP2K2 F133L NF2 Y66* TP53 C238F"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17019,
                    "pubMedId": 31082388,
                    "title": "Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31082388"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19437,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with melanoma harboring BRAF V600E developed progressive disease after 12 weeks of Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment, and progressed again after 106 weeks on anti-PD1 therapy including Opdivo (nivolumab) (90 weeks) followed by Keytruda (pembrolizumab), B2M V5Lfs*30, LRP1B W1344*, MAP2K2 F133L, NF2 Y66*, and TP53 C238F were identified in the post-progression biopsy in addition to BRAF V600E (PMID: 31082388).",
            "molecularProfile": {
                "id": 34105,
                "profileName": "B2M V5Lfs*30 BRAF V600E LRP1B W1344* MAP2K2 F133L NF2 Y66* TP53 C238F"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17019,
                    "pubMedId": 31082388,
                    "title": "Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31082388"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26954,
            "profileName": "TP53 C238F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34105,
            "profileName": "B2M V5Lfs*30 BRAF V600E LRP1B W1344* MAP2K2 F133L NF2 Y66* TP53 C238F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 94019,
            "transcript": "NM_001126118",
            "gDna": "chr17:g.7673790C>A",
            "cDna": "c.713G>T",
            "protein": "p.C238F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 94013,
            "transcript": "NM_000546",
            "gDna": "chr17:g.7674250C>A",
            "cDna": "c.713G>T",
            "protein": "p.C238F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 94017,
            "transcript": "NM_001126114",
            "gDna": "chr17:g.7674250C>A",
            "cDna": "c.713G>T",
            "protein": "p.C238F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 94012,
            "transcript": "NM_001276761",
            "gDna": "chr17:g.7673790C>A",
            "cDna": "c.713G>T",
            "protein": "p.C238F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 94011,
            "transcript": "NM_001126112",
            "gDna": "chr17:g.7674250C>A",
            "cDna": "c.713G>T",
            "protein": "p.C238F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 94014,
            "transcript": "NM_001276760",
            "gDna": "chr17:g.7673790C>A",
            "cDna": "c.713G>T",
            "protein": "p.C238F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 94015,
            "transcript": "NM_001126113",
            "gDna": "chr17:g.7674250C>A",
            "cDna": "c.713G>T",
            "protein": "p.C238F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 94018,
            "transcript": "NM_001276696",
            "gDna": "chr17:g.7673790C>A",
            "cDna": "c.713G>T",
            "protein": "p.C238F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 94016,
            "transcript": "NM_001276695",
            "gDna": "chr17:g.7673790C>A",
            "cDna": "c.713G>T",
            "protein": "p.C238F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}